Personalis at Immuno UK: October 13-14, 2021


Erin Newburn, PhD

Erin Newburn, PhD
Director, Field Applications Scientist
Personalis, Inc.

Wednesday, OCT 13 | 2:45 PM BST

Maximizing Immuno-Oncology Biomarker Discovery with the Universal Cancer Immunogenomics Platform ImmunoID NeXT

  • To enable the identification of composite biomarkers that combine tumor- and immune-related information from both DNA and RNA, we have developed the Personalis NeXT platform
  • By utilizing the expansive feature set, individual analytes can be combined to construct composite biomarker scores that correlate with immunotherapy response.
  • In a cohort of 51 late-stage melanoma patients, the integration of neoantigen burden, HLA LOH, and APM mutational data formed a neoantigen-based composite neoantigen (NEOPS) that more accurately predicted response to checkpoint blockade than other markers such as TMB.
  • The platform has been analytically validated and optimized for use with limited FFPE tissue samples, making it ideal for both research and clinical applications.

Connect with us at Immuno UK 2021